New Blood Test for Chronic Fatigue Syndrome
Researchers are exploring new avenues to diagnose chronic fatigue syndrome (CFS), a complex and enigmatic illness. A recent study published on October 8 in the Journal of Translational Medicine highlights how scientists in the UK have developed a method to identify epigenetic changes in the immune cells of individuals suffering from this condition, often referred to as myalgic encephalomyelitis (ME).
This debilitating, long-term illness affects an estimated 17 to 24 million people globally, but these figures are rough estimates due to the lack of reliable diagnostic methods for such a poorly understood condition.
The study’s findings suggest that this epigenetic test could pave the way for a clinical biomarker for ME/CFS. Dmitry Pshezhetskiy, an academic and clinician from the University of East Anglia, Norwich, and the study’s lead author, pointed out in a press release that many patients have spent years undiagnosed or misdiagnosed due to a lack of definitive tests. He expressed hope that this discovery could lead to a simple blood test to confirm diagnoses, potentially allowing for earlier intervention and improved management.
While the results have been cautiously welcomed by some in the field, there’s an acknowledgment that the study was small, and further research is necessary to convert this technique into a practical clinical tool.
Understanding Epigenetic Markers
The exact mechanisms behind ME/CFS are still a bit murky. However, it’s increasingly accepted that immune dysregulation is one of the significant factors associated with the condition. The researchers had previously created an assay to detect epigenetic changes in immune cells from blood samples, which they used to find signatures for various conditions, including rheumatoid arthritis.
In this study, they examined blood samples from 47 individuals with severe ME/CFS and compared them with samples from 61 healthy participants. The assay demonstrated a striking 96% accuracy in identifying those with ME/CFS.
They found a network of genomic alterations linked to immune and inflammatory signaling, which corroborates the notion of immune dysregulation in ME/CFS. Additionally, they connected these changes to specific non-coding DNA regions, which may help unravel the genetic roles in the condition, leading to a deeper understanding.
“It’s exciting that they brought this method into the discussion,” says Katie Glass, a molecular biologist studying ME/CFS at Cornell University. “But I think my enthusiasm is tempered a bit, as the cohort was quite small and focused only on severe cases.”
Glass also noted that numerous studies analyzing different biological elements have highlighted various potential markers for ME/CFS, drawing on her own experience as someone who previously dealt with the condition but has since recovered.
